Biosimilars cost less, but do they incur in indirect costs due to less dis control or more AE? DANBIO study (>1,300 pts w/ IA) Costs similar or decreased 9 mo after mandatory switching to ADA biosimilar (GP2017 or SB5) Decrease 15% GP2017 switchers #EULAR23 POS0376 @RheumNow https://t.co/bAeqYhNgf0